NPI: 1861440810 · ORANGE PARK, FL 32073 · Internal Medicine Physician · NPI assigned 05/04/2006
Authorized official CHRISTMAN, ANDREW controls 20+ related entities in our dataset. Read more
| Authorized Official | CHRISTMAN, ANDREW (CEO) |
| NPI Enumeration Date | 05/04/2006 |
Other providers sharing the same authorized official: CHRISTMAN, ANDREW
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 9,062 | $37K |
| 2019 | 118,684 | $1.94M |
| 2020 | 98,941 | $1.36M |
| 2021 | 61,880 | $505K |
| 2022 | 27,136 | $102K |
| 2023 | 10,067 | $7K |
| 2024 | 5,166 | $12K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 14,493 | 12,373 | $1.29M |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 55,458 | 47,054 | $1.23M |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 34,110 | 30,124 | $870K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1,960 | 1,941 | $153K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1,599 | 1,555 | $124K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 1,276 | 1,217 | $97K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 511 | 502 | $39K |
| 99204 | Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 330 | 306 | $33K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 4,617 | 4,529 | $15K |
| 64493 | 89 | 81 | $15K | |
| 90698 | 693 | 689 | $14K | |
| 80356 | 6,321 | 5,555 | $7K | |
| 99203 | Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 106 | 105 | $6K |
| 99215 | Prolong outpt/office vis | 190 | 173 | $6K |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | 1,105 | 321 | $5K |
| 99222 | Initial hospital care, per day, moderate complexity | 193 | 140 | $5K |
| 80348 | 6,947 | 6,103 | $4K | |
| 99232 | Subsequent hospital care, per day, moderate complexity | 701 | 154 | $4K |
| 80354 | 6,962 | 6,134 | $4K | |
| 80361 | 5,382 | 4,709 | $4K | |
| 80358 | 6,593 | 5,794 | $4K | |
| 80362 | 5,391 | 4,724 | $3K | |
| 80365 | 4,818 | 4,189 | $3K | |
| 99381 | 39 | 17 | $3K | |
| 90633 | 349 | 348 | $3K | |
| 90961 | 235 | 201 | $2K | |
| 90744 | 256 | 237 | $2K | |
| 90686 | 627 | 625 | $2K | |
| 80346 | 1,940 | 1,721 | $2K | |
| 80324 | 1,386 | 1,230 | $2K | |
| 01936 | 38 | 35 | $2K | |
| 99442 | 118 | 102 | $2K | |
| 80353 | 1,894 | 1,691 | $1K | |
| 90707 | 37 | 37 | $1K | |
| 90960 | End-stage renal disease related services monthly, for patients 20 years and older, with 4 or more face-to-face visits | 107 | 89 | $903.44 |
| 90700 | 26 | 26 | $890.18 | |
| 80372 | 504 | 450 | $592.30 | |
| 90651 | 70 | 68 | $580.00 | |
| 90461 | 1,810 | 1,745 | $576.00 | |
| 01992 | 12 | 12 | $533.31 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 397 | 305 | $508.99 |
| 36415 | Collection of venous blood by venipuncture | 622 | 563 | $492.01 |
| 20553 | 432 | 403 | $473.19 | |
| 90696 | 24 | 24 | $430.00 | |
| 80359 | 415 | 373 | $325.50 | |
| 20610 | 24 | 16 | $321.11 | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | 2,159 | 2,079 | $316.21 |
| 80373 | 37 | 34 | $238.00 | |
| 90670 | 1,200 | 1,188 | $230.00 | |
| 99173 | 321 | 243 | $218.83 | |
| 11721 | 113 | 94 | $208.37 | |
| 80053 | Comprehensive metabolic panel | 13 | 12 | $191.60 |
| 72100 | 71 | 59 | $171.12 | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 92 | 69 | $142.66 |
| 81002 | 1,000 | 917 | $114.53 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 216 | 192 | $95.91 |
| 97597 | 16 | 14 | $88.30 | |
| 93000 | 28 | 26 | $87.93 | |
| 81025 | 1,189 | 1,051 | $82.43 | |
| 90680 | 559 | 556 | $70.00 | |
| 1031F | 5,299 | 4,698 | $65.15 | |
| 20550 | 69 | 64 | $62.31 | |
| 90734 | 30 | 29 | $60.00 | |
| 90648 | 49 | 49 | $60.00 | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 238 | 114 | $59.23 |
| 64495 | 59 | 54 | $57.01 | |
| 64494 | 89 | 81 | $57.01 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 211 | 203 | $50.89 |
| 1125F | 6,213 | 5,525 | $48.73 | |
| 1159F | 13,530 | 12,005 | $33.73 | |
| 3074F | 11,402 | 10,273 | $33.05 | |
| 73630 | 21 | 13 | $32.22 | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 193 | 177 | $26.10 |
| 90756 | 13 | 13 | $21.22 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 135 | 101 | $19.86 |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | 10,868 | 9,322 | $17.33 |
| 80061 | Lipid panel | 14 | 14 | $16.60 |
| 99407 | 305 | 296 | $14.60 | |
| 2000F | 18,296 | 15,575 | $13.29 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 146 | 140 | $11.86 |
| 1160F | 14,333 | 12,723 | $10.63 | |
| 90715 | 12 | 12 | $10.00 | |
| 90710 | 29 | 29 | $10.00 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 81 | 72 | $1.93 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 148 | 76 | $0.85 |
| 1126F | 6,249 | 5,330 | $0.71 | |
| 3078F | 10,819 | 9,377 | $0.55 | |
| 99499 | 110 | 100 | $0.48 | |
| G9902 | Patient screened for tobacco use and identified as a tobacco user | 2,940 | 2,675 | $0.16 |
| 3061F | 34 | 34 | $0.14 | |
| 3079F | 3,616 | 3,293 | $0.13 | |
| 2001F | 19,636 | 16,865 | $0.13 | |
| 3075F | 920 | 884 | $0.10 | |
| 3008F | 21,241 | 18,427 | $0.05 | |
| 3077F | 404 | 376 | $0.03 | |
| 1034F | 780 | 715 | $0.03 | |
| G0444 | Annual depression screening, 5 to 15 minutes | 32 | 25 | $0.01 |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 2,100 | 1,907 | $0.00 |
| 0521F | 97 | 90 | $0.00 | |
| 1032F | 48 | 48 | $0.00 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 123 | 109 | $0.00 |
| 3080F | 494 | 439 | $0.00 | |
| 1000F | 76 | 63 | $0.00 | |
| 1036F | 1,049 | 889 | $0.00 | |
| 90716 | 24 | 24 | $0.00 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 15 | 14 | $0.00 |
| 1111F | 34 | 30 | $0.00 | |
| 96127 | 16 | 16 | $0.00 | |
| 4188F | 12 | 12 | $0.00 | |
| 1170F | 14 | 12 | $0.00 | |
| G9906 | Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) | 22 | 22 | $0.00 |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 14 | 14 | $0.00 |
| 99406 | 13 | 12 | $0.00 |